Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2004 1
2005 1
2018 1
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
[Proton pump inhibitors in pediatrics].
Faure C, Pelatan C, Languepin J. Faure C, et al. Among authors: languepin j. Arch Pediatr. 1999 Jun;6(6):650-6. doi: 10.1016/s0929-693x(99)80298-x. Arch Pediatr. 1999. PMID: 10394458 Review. French.
They act on the final step of gastric acid secretion by completely inhibiting the ATPase (proton pump) at the surface of the gastric parietal cells, thus yielding long term inhibition which is not correlated with the plasma concentration of the drug, in contrast to the eff …
They act on the final step of gastric acid secretion by completely inhibiting the ATPase (proton pump) at the surface of the gastric parieta …
Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis.
Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F, Collet C, Mas E, Languepin J, Fayon M, Beaufils F, Mittaine M. Bui S, et al. Among authors: languepin j. Front Pediatr. 2021 Nov 15;9:744705. doi: 10.3389/fped.2021.744705. eCollection 2021. Front Pediatr. 2021. PMID: 34869102 Free PMC article.
Conclusion: In F508del homozygote adolescents, real-life long-term LUM/IVA improved the ppFEV1 trajectory, particularly in the youngest patients, nutritional status, and sweat chloride concentration but not exacerbation rates or radiological scores. ...
Conclusion: In F508del homozygote adolescents, real-life long-term LUM/IVA improved the ppFEV1 trajectory, particularly in the younge …
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventil

…

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence

…
A European Survey on Digestive Perianastomotic Ulcerations, a Rare Crohn-like Disorder Occurring in Children and Young Adults.
Madre C, Mašić M, Prlenda-Touilleux D, Brueckner A, Koletzko S, Fabre A, Viala J, Lima R, Enaud R, Lemale J, Kolho KL, Bergoin C, Martinez-Vinson C, Dugelay E, Alvisi P, Aloi M, Miele E, Duclaux-Loras R, Nachury M, Languepin J, Willot S, Dupont-Lucas C, Mosca A, Tzivinikos C, Shamasneh I, Kolaček S, Hugot JP; pediatric GETAID group and the ESPGHAN IBD Porto group. Madre C, et al. Among authors: languepin j. J Pediatr Gastroenterol Nutr. 2021 Sep 1;73(3):333-337. doi: 10.1097/MPG.0000000000003200. J Pediatr Gastroenterol Nutr. 2021. PMID: 34117192
OBJECTIVES: Digestive perianastomotic ulcerations (DPAU) resembling Crohn disease lesions are long-term complications of intestinal resections, occurring in children and young adults. ...
OBJECTIVES: Digestive perianastomotic ulcerations (DPAU) resembling Crohn disease lesions are long-term complications of intestinal r …
Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient.
Rouard C, Garnier F, Leraut J, Lepainteur M, Rahajamananav L, Languepin J, Ploy MC, Bourgeois-Nicolaos N, Doucet-Populaire F. Rouard C, et al. Among authors: languepin j. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e00720-18. doi: 10.1128/AAC.00720-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30275089 Free PMC article.
Although LZD resistance is rare, it has been described as often associated with long-term treatments. Thirteen MRSA strains isolated over 5 years from one CF patient were studied for LZD resistance emergence and subjected to whole-genome sequencing (WGS). ...
Although LZD resistance is rare, it has been described as often associated with long-term treatments. Thirteen MRSA strains isolated …
Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Lamireau T, Cézard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J; French-Speaking Group for Pediatric Gastroenterology Nutrition. Lamireau T, et al. Among authors: languepin j. Inflamm Bowel Dis. 2004 Nov;10(6):745-50. doi: 10.1097/00054725-200411000-00008. Inflamm Bowel Dis. 2004. PMID: 15626892
Treatment with infliximab is well tolerated and effective in most children and adolescents with Crohn's disease that is refractory to conventional immunosuppressive therapy. Nevertheless, long-term efficacy remains to be shown, and further studies are urgently needed to pr …
Treatment with infliximab is well tolerated and effective in most children and adolescents with Crohn's disease that is refractory to conven …
Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children.
Dupont C, Leluyer B, Maamri N, Morali A, Joye JP, Fiorini JM, Abdelatif A, Baranes C, Benoît S, Benssoussan A, Boussioux JL, Boyer P, Brunet E, Delorme J, François-Cecchin S, Gottrand F, Grassart M, Hadji S, Kalidjian A, Languepin J, Leissler C, Lejay D, Livon D, Lopez JP, Mougenot JF, Risse JC, Rizk C, Roumaneix D, Schirrer J, Thoron B, Kalach N. Dupont C, et al. Among authors: languepin j. J Pediatr Gastroenterol Nutr. 2005 Nov;41(5):625-33. doi: 10.1097/01.mpg.0000181188.01887.78. J Pediatr Gastroenterol Nutr. 2005. PMID: 16254521 Clinical Trial.
CONCLUSION: This 3-month study in 96 constipated children aged 6 months to 3 years confirms the long-term tolerance of PEG 4000 in pediatrics and indicates a PEG efficacy similar to or greater than that of lactulose....
CONCLUSION: This 3-month study in 96 constipated children aged 6 months to 3 years confirms the long-term tolerance of PEG 4000 in pe …
[Management of Hirschsprung's disease during the neonatal period].
de Lagausie P, Aubert F, Hankard GF, Languepin J, Aigrain Y. de Lagausie P, et al. Among authors: languepin j. Ann Chir. 1998;52(10):1028-32. Ann Chir. 1998. PMID: 9951105 French.
The management consists of septic complications of treatment, and a variable "pull-through" procedure, immediately or at a later date. Long-term follow-up is an important component of patient care....
The management consists of septic complications of treatment, and a variable "pull-through" procedure, immediately or at a later date. Long- …